Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.

Alessio Aghemo,Marcello Persico,Roberta D'Ambrosio,Massimo Andreoni,Erica Villa,Abhi Bhagat,Valentina Gallinaro,Giuliana Gualberti,Rocco Cosimo Damiano Merolla,Antonio Gasbarrini

PloS one（2023）

引用 0|浏览22

暂无评分

摘要

Results from this real-world Italian cohort demonstrated the safety and effectiveness of 8-week G/P, with SVR12 rate >95%, even in elderly patients. These findings further support real-world evidence of the use of short-course G/P treatment in all patients with CC, including those with GT3, and those with advanced liver disease.

查看译文

关键词

hcv patients,glecaprevir/pibrentasvir,crest study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要